SÍNDROME NEUROLÉPTICO MALIGNO: PRESENTACIÓN DE DOS CASOS Y REVISIÓN DEL TEMA

Juan D. Barrios; Ribana Molino

Enviado octubre 14, 2024

Publicado 2026-04-06

Artículos de Investigación

Vol. 16 Núm. 2 (2003): Revista Médico Científica

SÍNDROME NEUROLÉPTICO MALIGNO: PRESENTACIÓN DE DOS CASOS Y REVISIÓN DEL TEMA

Juan D. Barrios⁺⁻
Ribana Molino⁺⁻

PDF

Citación:

DOI: ND

Publicado: 2026-04-06

Derechos de autor 2024 Revista médico científica

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.

Resumen

Se describen las historias clínicas de 2 pacientes con criterios diagnósticos de Síndrome Neuroléptico Maligno que estuvieron hospitalizados en el Servicio de Medicina Interna del Hospital Santo Tomás.
Ambos pacientes eran del sexo femenino y tenían antecedentes de tratamiento con neurolépticos por distintos trastornos psiquiátricos, con posterior desarrollo de rigidez muscular, hipertermia, alteración del estado de conciencia, inestabilidad autonómica y aumento en los niveles de creatinina loslokinasa.
Se hace revisión del Síndrome Neuroléptico Maligno y su tratamiento.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Guze SH, Baxter LR Jr. Current Concepts. Neuroleptic Malignant Syndrome. N Engl J Med 1985; 313: 163 - 6.
Caroff Sn, Mann SC. Neuroleptic Malignant Syndrome. Med Clin North Am 1993; 77: 185 - 202.
Sholevar DP. Neuroleptic Malignant Syndrome. Disponible en URL : http://www.emedicine.com/med/topic2614.htm.
Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic Malignant Syndrome. Br J Anaesth 2000; 85: 129 - 35.
Challoner K. Toxicity, Neuroleptic Agents. Disponible en URL: http://www.emedicine.com/emerg/topic.338.htm.
Simon HB. Hyperthermia. N Engl J Med 1993; 329: 483 - 7.
Heiman-Patterson TD. Neuroleptic Malignant Syndrome and Malignant Hyperthermia. Important issues lor the medical consultant. Med Clin North Am 1993; 77: 477 - 92.
Chan-Tack KM. Neuroleptic Malignant Syndrome Due to Promethazine. South Med J 1999; 92: 1017 - 8.
Singh SP,Giridhar C,AvasthiA. Neuroieptic Malignant Syndrome With Trilluperidol. Sr J Psychiatry 1989; 155: 561 - 5.
Manser TJ, Warner JF. Neuroleptic Malignant Syndrome Associated with Prochlorperazine. South Med J 1990; 83: 73 - 4. 11. Philibert RA, Adam LA, Frank FM. Carney-Doebbeling C. Olanzapine Usage Associated With Neuroleptic Malignant Syndrome. Psychosomatics 2001; 42: 528 - 9.
Serry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic Malignant Syndrome in an Adolescent Receiving Olanzapine-Lithium Combínation Therapy. Pharmacotherapy 2003; 23: 255 - 9.
Reeves RR, Torres RA, Liberto V, Hart RH. Atypical Neuroleptic Malignant Syndrome Associated With Olanzapine.
Pharmacotherapy 2002; 22: 641 - 4.
Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic Malignant Syndrome and Quetiapine (Letter)(erratum publicado en Am J Psychiatry 2002; 156:892). Am J Psychiatry 2002; 159: 149 - 50. 15. Cassidy EM, O'Kearne V. Neuroleptic Malignant Syndrome alter Venlalaxine (Letter). The Lancet 2000; 355: 2164 - 5.
Sharma R, Trappler S, Ng YK, Leeman C. Risperidone-Induced Neuroleptic Malignant Syndrome. Ann Pharmacother 1996 ; 30 : 775 - 8.
Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, et al. Association 01the Taq1 Polymorphism 01the Dopamine 0 2 Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome. Am J Psychiatry 2001; 158: 1714 - 6.
Patel U,A grawal M. Krishnan P, Niranjan S. Neuroleptic Malignant Syndrome Presenling as Pulmonary Edema and Severe Bronchorrhea. J Natl Med Assoc 2002; 94: 279 - 82.
Srinivasan AV, Murugappan M, Krishnamurthy SG, Sayeed ZA. Neuroleptic Malignant Syndrome. J Neurol Neurosurg Psychiatry 1990; 53: 514 - 6.
Mueller PS, Vester JW, Fermaglich J. Neuroleptic Malignant Syndrome. Successful Treatment with bromocriptine.JAMA 1983; 249: 386 - 8.
HarlandCC,O'LearyMM,WintersR,OwensJ, HayesB,Melikian V. Neuroleptic Malignant Syndrome : a case tor electroconvulsive therapy. Postgrad Med J 1990; 66 (771): 49 - 51.
Padgett R, Lipman E. Use 01 Neuroleptics alter an Episode 01 Neuroleptic Malignant Syndrome. Can J Psychiatry 1989; 34: 323- 5.

Palabras clave

PDF

Resumen visto - 1 veces
PDF descargado - 0

Licencia

Content Top

[1] Guze SH, Baxter LR Jr. Current Concepts. Neuroleptic Malignant Syndrome. N Engl J Med 1985; 313: 163 - 6.

[2] Caroff Sn, Mann SC. Neuroleptic Malignant Syndrome. Med Clin North Am 1993; 77: 185 - 202.

[3] Sholevar DP. Neuroleptic Malignant Syndrome. Disponible en URL : http://www.emedicine.com/med/topic2614.htm.

[4] Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic Malignant Syndrome. Br J Anaesth 2000; 85: 129 - 35.

[5] Challoner K. Toxicity, Neuroleptic Agents. Disponible en URL: http://www.emedicine.com/emerg/topic.338.htm.

[6] Simon HB. Hyperthermia. N Engl J Med 1993; 329: 483 - 7.

[7] Heiman-Patterson TD. Neuroleptic Malignant Syndrome and Malignant Hyperthermia. Important issues lor the medical consultant. Med Clin North Am 1993; 77: 477 - 92.

[8] Chan-Tack KM. Neuroleptic Malignant Syndrome Due to Promethazine. South Med J 1999; 92: 1017 - 8.

[9] Singh SP,Giridhar C,AvasthiA. Neuroieptic Malignant Syndrome With Trilluperidol. Sr J Psychiatry 1989; 155: 561 - 5.

[10] Manser TJ, Warner JF. Neuroleptic Malignant Syndrome Associated with Prochlorperazine. South Med J 1990; 83: 73 - 4. 11. Philibert RA, Adam LA, Frank FM. Carney-Doebbeling C. Olanzapine Usage Associated With Neuroleptic Malignant Syndrome. Psychosomatics 2001; 42: 528 - 9.

[11] Serry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic Malignant Syndrome in an Adolescent Receiving Olanzapine-Lithium Combínation Therapy. Pharmacotherapy 2003; 23: 255 - 9.

[12] Reeves RR, Torres RA, Liberto V, Hart RH. Atypical Neuroleptic Malignant Syndrome Associated With Olanzapine.

[13] Pharmacotherapy 2002; 22: 641 - 4.

[14] Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic Malignant Syndrome and Quetiapine (Letter)(erratum publicado en Am J Psychiatry 2002; 156:892). Am J Psychiatry 2002; 159: 149 - 50. 15. Cassidy EM, O'Kearne V. Neuroleptic Malignant Syndrome alter Venlalaxine (Letter). The Lancet 2000; 355: 2164 - 5.

[15] Sharma R, Trappler S, Ng YK, Leeman C. Risperidone-Induced Neuroleptic Malignant Syndrome. Ann Pharmacother 1996 ; 30 : 775 - 8.

[16] Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, et al. Association 01the Taq1 Polymorphism 01the Dopamine 0 2 Receptor Gene With Predisposition to Neuroleptic Malignant Syndrome. Am J Psychiatry 2001; 158: 1714 - 6.

[17] Patel U,A grawal M. Krishnan P, Niranjan S. Neuroleptic Malignant Syndrome Presenling as Pulmonary Edema and Severe Bronchorrhea. J Natl Med Assoc 2002; 94: 279 - 82.

[18] Srinivasan AV, Murugappan M, Krishnamurthy SG, Sayeed ZA. Neuroleptic Malignant Syndrome. J Neurol Neurosurg Psychiatry 1990; 53: 514 - 6.

[19] Mueller PS, Vester JW, Fermaglich J. Neuroleptic Malignant Syndrome. Successful Treatment with bromocriptine.JAMA 1983; 249: 386 - 8.

[20] HarlandCC,O'LearyMM,WintersR,OwensJ, HayesB,Melikian V. Neuroleptic Malignant Syndrome : a case tor electroconvulsive therapy. Postgrad Med J 1990; 66 (771): 49 - 51.

[21] Padgett R, Lipman E. Use 01 Neuroleptics alter an Episode 01 Neuroleptic Malignant Syndrome. Can J Psychiatry 1989; 34: 323- 5.

Imagen de portada

Resumen

Descargas

Citas

Palabras clave

Licencia